The US Food and Drug Administration (FDA) approved Genzyme Corporation’s venglustat (Infilbray), making it the first treatment authorized for neurological symptoms of type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 lb).
The approval introduces a treatment that crosses the blood-brain barrier to address neurological manifestations of GD3, a rare inherited lysosomal storage disorder characterized by impaired breakdown of glucosphingolipids. Unlike type 1 Gaucher disease, GD3 involves progressive neurological impairment, including difficulties with balance, coordination, speech, memory, and cognition. Venglustat inhibits glucosylceramide synthase, reducing accumulation of glucosphingolipids in the body and brain.
The decision was supported by a randomized, double-blind, multicenter clinical trial involving 43 patients aged 12 years and older with GD3 who had previously received enzyme replacement therapy and achieved stable systemic disease.
Participants received either oral venglustat once daily or intravenous enzyme replacement therapy every 2 weeks for 52 weeks. Treatment efficacy was assessed using 2 measures of neurological manifestations, including ataxia and cognitive function.
At week 52, patients receiving venglustat showed improvement in a combined neurological assessment compared with those receiving enzyme replacement therapy for nonneurological manifestations of GD3. The FDA announcement did not provide numerical estimates of treatment effects.
The most frequently reported adverse effects included gastrointestinal symptoms and mood-related changes. Serious psychiatric risks, including suicidal ideation and behavior, were also reported. Animal studies identified potential risks of visual clouding in younger patients and adverse effects on fetal development when the drug is taken during pregnancy.
The FDA granted venglustat Orphan Drug designation and Priority Review, recognizing its intended use in a rare disease and its potential to addressan unmet therapeutic need.
Source: FDA
